{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Epigral Ltd
Epigral Ltd Falls 4.65% Amid Volatility: 2 Key Trading Days Define Week
Epigral Ltd’s stock experienced a turbulent week, closing at Rs.990.40 on 6 February 2026, down 4.65% from the previous Friday’s close of Rs.1,038.70. This decline contrasted with the Sensex’s 1.51% gain over the same period, highlighting the stock’s continued underperformance amid mixed market signals and sector-specific challenges.
Epigral Ltd Hits Intraday High with Strong 7.8% Surge on 3 Feb 2026
Epigral Ltd recorded a robust intraday performance on 3 Feb 2026, surging to a day’s high of Rs 1001.65, marking a 7.98% increase from the previous close. The stock outperformed its sector and the broader market, reflecting notable trading momentum within the Specialty Chemicals industry.
Epigral Ltd Stock Falls to 52-Week Low of Rs.933.45 Amid Continued Downtrend
Epigral Ltd, a player in the Specialty Chemicals sector, recorded a fresh 52-week low of Rs.933.45 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and valuation metrics.
Epigral Ltd Hits Intraday Low Amidst Significant Price Pressure
Epigral Ltd’s shares declined sharply today, touching an intraday low of Rs 965, marking a new 52-week low as the stock underperformed both its sector and the broader market amid widespread selling pressure.
Epigral Ltd Stock Falls to 52-Week Low Amidst Continued Underperformance
Epigral Ltd, a key player in the Specialty Chemicals sector, has touched a new 52-week low, closing just 0.02% above its lowest price of Rs 997.7. This marks a significant point in the stock’s recent trajectory, reflecting ongoing challenges in both its near-term and long-term performance metrics.
Epigral Ltd is Rated Sell
Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 February 2026, providing investors with the latest insights into the company’s performance and outlook.
Are Epigral Ltd latest results good or bad?
Epigral Ltd's latest Q3 FY26 results are concerning, showing a 7.46% year-on-year decline in net sales and a 62.26% drop in net profit after tax, alongside significant margin compression and rising costs, indicating operational challenges and reduced investor confidence.
Epigral Ltd Falls 2.54% Amidst 52-Week Lows and Earnings Pressure
Epigral Ltd’s stock closed the week at Rs.1,038.70, down 2.54% from Rs.1,065.75 the previous Friday, underperforming the Sensex which gained 1.62% over the same period. The week was marked by a persistent downtrend with the stock hitting successive 52-week lows amid subdued financial results and rising interest expenses, contrasting sharply with the broader market’s positive momentum.
Epigral Q3 FY26: Margin Compression and Profit Decline Signal Growing Headwinds
Epigral Ltd., a small-cap specialty chemicals manufacturer with a market capitalisation of ₹4,463 crores, reported a consolidated net profit of ₹39.11 crores for Q3 FY26, marking a sharp decline of 62.26% year-on-year and 23.64% quarter-on-quarter. The results underscore mounting operational challenges as the company grapples with severe margin compression and weakening profitability despite marginal revenue growth.
Epigral Ltd Stock Falls to 52-Week Low of Rs.1010.85
Epigral Ltd, a player in the Specialty Chemicals sector, recorded a fresh 52-week low of Rs.1010.85 today, marking a significant milestone in its ongoing price decline. Despite a modest intraday recovery, the stock remains below all key moving averages, reflecting persistent downward pressure amid broader market volatility.
Epigral Ltd Stock Falls to 52-Week Low of Rs.1034.15
Epigral Ltd, a key player in the Specialty Chemicals sector, recorded a fresh 52-week low of Rs.1034.15 today, marking a significant milestone in its ongoing price decline. The stock has been under pressure for several sessions, reflecting a combination of subdued financial performance and broader market dynamics.
Epigral Ltd Stock Hits 52-Week Low Amidst Continued Downtrend
Epigral Ltd, a player in the Specialty Chemicals sector, recorded a fresh 52-week low of Rs.1044.1 today, marking a significant milestone in its ongoing price decline. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its valuation and performance metrics.
Epigral Ltd Stock Falls to 52-Week Low of Rs.1045.55 Amid Continued Downtrend
Epigral Ltd, a key player in the Specialty Chemicals sector, recorded a fresh 52-week low of Rs.1045.55 today, marking a significant milestone in its ongoing price decline. The stock has underperformed both its sector and broader market indices, reflecting persistent pressures on its valuation and financial performance.
Epigral Ltd Stock Falls to 52-Week Low of Rs.1070.3 Amidst Continued Underperformance
Epigral Ltd, a key player in the Specialty Chemicals sector, recorded a fresh 52-week low today, with its stock price falling to Rs.1070.3. This marks a significant decline amid a broader market environment that has seen the Sensex dip by 0.35% to 82,017.32, reflecting ongoing pressures on the company’s share performance.
Epigral Ltd is Rated Sell
Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Epigral Ltd Stock Falls to 52-Week Low of Rs.1106 Amid Continued Downtrend
Epigral Ltd, a key player in the Specialty Chemicals sector, has reached a new 52-week low of Rs.1106, marking a significant decline amid a sustained downward trend. The stock’s recent performance reflects a series of challenges impacting its valuation and market standing.
Epigral Ltd Stock Hits 52-Week Low at Rs.1110 Amidst Continued Downtrend
Epigral Ltd, a player in the Specialty Chemicals sector, recorded a fresh 52-week low of Rs.1110 today, marking a significant milestone in its ongoing price decline. Despite a slight intraday recovery, the stock remains under pressure, reflecting persistent challenges in its financial performance and market positioning.
Epigral Ltd Falls 10.37%: Six-Day Slide Amid Profit Declines and Rising Costs
Epigral Ltd’s shares declined sharply over the week ending 9 January 2026, falling 10.37% from Rs.1,248.00 to Rs.1,118.60, significantly underperforming the Sensex’s 2.62% drop. The stock hit multiple 52-week lows amid sustained selling pressure, deteriorating financial results, and increased interest expenses, reflecting a challenging environment for the specialty chemicals company.
Epigral Ltd is Rated Sell by MarketsMOJO
Epigral Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 26 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with the latest insights into the company’s performance and outlook.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
